Grifols S.A. — Capital/Financing Update 2021

Apr 7, 2021

6-K 1 tm2112368d1_6k.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month April 2021

(Commission File No. 001-35193)

Grifols, S.A.

(Translation of registrant’s name into English)

Field: Rule-Page

Field: /Rule-Page

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

Field: Rule-Page

Field: /Rule-Page

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes o No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes o No x

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- . .

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Grifols, S.A.

TABLE OF CONTENTS

Item		Sequential Page Number
1.	Other Relevant Information, dated April
7, 2021	3

Field: Page; Sequence: 2

Field: /Page

Grifols, S.A. Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona - ESPAÑA Tel. [34] 935 710 500 Fax [34] 935 710 267 www.grifols.com

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. (" Grifols ") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that it has closed the transaction to acquire 7 U.S. based plasma donation centers from Kedplasma, LLC. (a company belonging to the Kedrion Group) for a total purchase price of USD 55.2 million. The 7 centers acquired are authorized by the U.S. Food and Drug Administration (FDA) and European health authorities and collect approximately 240,000 liters of plasma. Grifols will have immediate access to the plasma obtained from these centers.

This acquisition reflects Grifols’ commitment to enlarge its plasma supply through organic and inorganic growth.

Since January 2021, Grifols’ efforts to accelerate the execution of its strategic expansion plan have enabled it to immediately leverage an additional approximately 1.4 million liters of plasma per year. At the same time, the company continues its efforts to open new centers.

The transaction is financed from Grifols’ own resources.

This acquisition is aligned with Grifols’ global expansion and plasma-supply diversification strategy, with 296 plasma centers in the U.S. following this transaction and 55 in Europe across Germany, Austria and, recently Hungary. Likewise, Grifols remains committed to increasing its supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need.

In Barcelona, on 7 April 2021

Nuria Martín Barnés

Secretary to the Board of Directors

Field: Page; Sequence: 3

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

/s/ David I. Bell
Name:	David I. Bell
Title:	Authorized Signatory

Date: April 7, 2021

Field: Page; Sequence: 4; Options: Last

Field: /Page